Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by Mbxwatcheron Jun 04, 2024 1:31pm
115 Views
Post# 36071535

RE:RE:RE:Cross

RE:RE:RE:Cross

At least 2.1 million people in North and South America have been infected this year with dengue — a record-setting figure that scientists attribute in part to climate change.

The Pan American Health Organization says there have been about 2.1 million confirmed cases of the potentially fatal disease in the Americas since January. That’s already more than the record-setting mark of 2 million confirmed cases for all of 2023.

And this year’s figure could be much higher. As many as 5.1 million people may have been infected in North and South America, according to the Pan American Health Organization, the United Nations agency in charge of international health cooperation in the Americas.

The outbreak has pushed Puerto Rico, Peru and nine of Brazil’s 26 states to declare states of emergency. More than 1,800 people in the Americas have died this year from dengue.

“We already have a large number of cases this year, not only in Brazil but also Paraguay and Argentina and other countries — even Uruguay and areas where there has been no transmission of dengue for a century,” said Pan American Health Organization director Jarbas Barbosa in a March press briefing.

<< Previous
Bullboard Posts
Next >>